A single-arm phase 1/2a clinical trial (NCT04662099) was designed to evaluate the feasibility, safety, and efficacy of bispecific CS1/BCMA-targeted CAR-T cells in patients with r/r MM. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.